Business
Antengene Announces 2025 Interim Financial Results Highlighting Encouraging Data from Mid/Late-Stage Clinical Programs and Its Innovative TCE Technology Platform
Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) today announced its interim results for the period ending June 30, 2025, along with an update highlighting some of its recent achievements.
About this update from Antengene Corporation Limited
[{"type":"list","items":[{"val":[{"type":"text","content":"The Phase I/II CLINCH study of ATG-022 (CLDN18.2 antibody-drug conjugate) demonstrated promising results, showing robust clinical efficacy and a favorable safety profile in patients with gastric/gastroesophageal junction adenocarcinoma across high, low, and ultra-low CLDN18.2 expression levels. Supported by these results, ATG-022 was granted a Breakthrough Therapy designation by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA).","length":487,"tagName":"p"}]},{"val":[{"type":"text","content":"The Phase I/II STAMINA study of ATG-037 (Oral CD73 small molecule inhibitor) is progressing smoothly. The latest data show particularly encouraging efficacy in the CPI-resistant melanoma subgroup, with an objective response rate (ORR) of 36.4%, a disease control rate (DCR) of 100%, including 1 CR and 3 partial responses (PRs). In the CPI-resistant non-small cell lung cancer (NSCLC) subgroup, the ORR was 21.4%, the DCR was 71.4%, including 3 PRs.","length":454,"tagName":"p"}]},{"val":[{"type":"text","content":"Expanding its pipeline's therapeutic area to autoimmune diseases, Antengene released the preclinical data of ATG-201, a CD19 x CD3 TCE with steric hindrance masking technology. In non-human primate (NHP) models, repeated dosing of ATG-201 surrogate at 1mpk, 3mpk, and 6mpk was well tolerated and associated with very low cytokine release. ATG-201 is expected to enter clinical development in Q4 2025.","length":409,"tagName":"p"}]},{"val":[{"type":"text","content":"In the first half of 2025, XPOVIO® generated a revenue of RMB 53.2 million, which rose sharply by 70.6% period-over-period. In addition to the rapid revenue growth, the company's operational efficiency continued to improve, with sales and administrative expenses declining by 34.0% and 32.8% year-over-year, respectively.","length":335,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":1685,"olType":false},{"type":"text","content":"SHANGHAI and HONG KONG, Aug. 22, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) today announced its interim results for the period ending June 30, 2025, along with an update highlighting some of its recent achievements.","length":262,"tagName":"p"},{"type":"image","alt":"Logo (PRNewsfoto...